Revolution Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary

Revolution Medicines

05/08/2026 22:01

Revolution Medicines, Inc. RVMD.OQ reported a quarterly adjusted loss of $3.06​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.31.  The mean expectation of twenty analysts for the quarter was for a loss of $1.98 per share. Wall Street expected results to range from $-2.34 to -85 cents per share.
Reported revenue was zero​; analysts expected $16.37 million. 
Revolution Medicines, Inc.'s reported EPS for the quarter was a loss of $3.06​.
The company reported a quarterly loss of $644.37 million.
Revolution Medicines, Inc. shares had risen by 3.3% this quarter and gained 142.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Revolution Medicines, Inc. is $211.00, about 8.3% above its last closing price of $193.46
This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.98
-3.06
Missed
Mar. 31 2026 
-1.84
-2.29
Missed
Dec. 31 2025 
-1.58
-1.86
Missed
Sep. 30 2025 
-1.42
-1.61
Missed